IngredientsPhytoplankton is a collective term encompassing a vast and taxonomically diverse assemblage of photosynthetic microorganisms that drift in marine and freshwater environments. As a dietary supplement, the term almost always refers to specific species of marine microalgae selected for their nutritional profiles. Marine phytoplankton is made up of tiny organisms that live in ocean waters. In the ocean, omega-3 fatty acids are mostly synthesized by phytoplankton, and phytoplankton community composition is a major factor regulating the amount of omega-3 produced in a particular system.
The species most commonly used in commercially available dietary supplements include:
A meta-analysis of over 160 fatty acid profiles of 7 marine phytoplankton phyla reveals not only a phyla-specific, but also a highly class-specific PUFA production of marine phytoplankton. The highest EPA production per total fatty acids was found in 2 classes of Haptophyta and in Ochrophyta, while Dinophyta and the Haptophyte Emiliana huxleyi show the highest production of DHA.
The nutritional profile of a marine phytoplankton supplement depends almost entirely on the species inside it. Most products use Nannochloropsis gaditana. Common genera in supplements may include Nannochloropsis, Tetraselmis, and other marine microalgae selected for their content of omega-3 fatty acids (especially EPA), carotenoids, chlorophylls, vitamins, and trace minerals.
Phytoplankton supplements are commercially available in several forms:
Unlike open-water or pond-grown algae, many commercial products are cultivated entirely in a sealed photobioreactor, using only ultra-purified seawater, CO2, and sunlight. This design eliminates exposure to heavy metals, microplastics, pathogens, and ocean pollutants. Controlled cultivation allows scientists to tweak growth conditions for optimal production of fatty acids, polysaccharides, enzymes, and antioxidants.
Phytoplankton — as isolated, identified, and concentrated microorganisms — has no formal tradition of deliberate human use in any historical culture analogous to plant-based herbal medicine. Its role in human history is fundamentally ecological rather than ethnopharmacological. In the ocean, omega-3 fatty acids are mostly synthesized by phytoplankton, and populations around the world have benefited indirectly from phytoplankton through the consumption of fish and other marine animals that accumulate phytoplankton-derived nutrients up the food chain.
The direct use of microalgae as a human food does have limited documented historical precedent in certain cultures. The cyanobacterium Arthrospira (Spirulina) was reportedly consumed by the Aztecs of Mesoamerica in the form of dried cakes, and similar traditions existed around Lake Chad in Africa. However, these are distinct organisms from the marine microalgae now sold as phytoplankton supplements.
It is estimated that by 2050, the world's population will exceed 10 billion people, which will lead to a deterioration in global food security. To avoid aggravating this problem, FAO and WHO have recommended dietary changes to reduce the intake of animal calories and increase the consumption of sustainable, nutrient-rich, and calorie-efficient products. Moreover, due to the worldwide rising incidence of non-communicable diseases and the demonstrated impact of diet on the risk of these disorders, the current established food pattern is focused on the consumption of foods that have functionality for health. This modern context — not tradition — is the primary driver of phytoplankton's contemporary use as a supplement.
Species of Tetraselmis have been used as a laboratory model strain to study the effect of diverse conditions on their growth, survival and adaptation. Moreover, these species are frequently used in aquaculture due to their high nutritional value in terms of proteins and fatty acids, and their content in other biological compounds. This aquaculture use preceded and informed the development of human dietary applications.
Marine phytoplankton is an important source of healthy fats, including omega-3 fatty acids, phospholipids, and sterols. Phytoplankton is among the highest plant sources of eicosapentaenoic acid (EPA), which is an omega-3 fatty acid essential for good health. EPA is important for a variety of bodily functions, including brain function, cardiovascular health, and inflammation regulation.
For whole-cell Nannochloropsis gaditana, EPA constitutes 20–30% of total fatty acids (per Ma et al., 2016); protein makes up 30–45% of dry weight, with a complete amino acid profile; key pigments include chlorophyll a, violaxanthin, vaucheriaxanthin, and beta-carotene; and minerals include iron, magnesium, zinc, and B-group vitamins (variable by batch).
This makes marine phytoplankton an excellent source of EPA for vegetarians, vegans, and others who may not consume fatty fish or fish oil supplements. Omega-3 PUFAs are essential for the development and function of the brain, the nervous system, and eyes, as well as serving as a preventative for heart disease and inflammation. EPA and DHA in particular are highly sought after by the nutraceutical and pharmaceutical industry.
Fucoxanthin, belonging to the xanthophyll class of carotenoids, is a natural antioxidant pigment of marine algae, including brown macroalgae and diatoms, and represents approximately 10% of the total carotenoids in nature. The molecular structure of fucoxanthin is characterized by an unusual allenic bond, an epoxide group, and a conjugated carbonyl group in a polyene backbone, which is responsible for its strong antioxidant activity. In Nannochloropsis species, the primary carotenoids are violaxanthin, vaucheriaxanthin, and beta-carotene rather than fucoxanthin, which is more characteristic of diatoms such as Phaeodactylum tricornutum.
Additional phytonutrients present in Nannochloropsis oculata include omega-7 fatty acids, chlorophyll, carotenoids, coenzyme Q9 (CoQ9), and coenzyme Q10 (CoQ10).
A particularly distinctive biochemical feature of Tetraselmis chuii used in supplement preparations is its high content of the antioxidant enzyme superoxide dismutase. The ingredient derived from the microalga Tetraselmis chuii contains highly active antioxidant enzymes, particularly superoxide dismutase (SOD), which speeds the reaction that converts superoxide into ordinary molecular oxygen, thereby protecting cells; the ingredient has demonstrated high antioxidant capacity via high concentrations of SOD (38,000 IU per 100 g).
In addition to SOD, the ingredient contains a number of potentially bioactive compounds such as poly-unsaturated fatty acids (PUFAs), polyphenols, vitamins, carotenoids, and phytosterols.
The amino acid composition of Nannochloropsis and Tetraselmis has been assessed against reference values for essential amino acids (EAA) recommended by the Food and Agriculture Organization (FAO). Comparison of the EAA profile with the FAO reference pattern indicates that, overall, the EAA content of these microalgae is close to reference values indicative of good protein quality. However, methionine content is lower than stated by FAO.
Detailed analyses of edible microalgae show complex lipidomes, with hundreds of individual lipid species, including substantial proportions of polyunsaturated fatty acids such as EPA and, in some species, DHA. These studies confirm that microalgae can be dense sources of high-value dietary lipids and other nutrients.
The sugar composition of the polysaccharides from microalgae differs between species, and variations could contribute to differences in nutritional value. In N. oculata, glucose is the preponderant sugar content (68.2%), followed by fucose, galactose, mannose, rhamnose, ribose, and xylose in percentages below 10%. Beta-1,3-glucans are also notable in certain species such as Phaeodactylum tricornutum.
Marine phytoplankton species, particularly Nannochloropsis and Tetraselmis, contain a broad spectrum of vitamins, minerals, and amino acids packed into a remarkably small organism. B vitamins, magnesium, zinc, iron, and all amino acids the body cannot synthesize may be obtained from a single whole-food source.
Superoxide dismutase-rich Tetraselmis chuii has been reported to increase gene expression of nuclear factor erythroid 2-related factor 2 (NRF2) and related antioxidant enzymes in myoblast tissue culture models. Human research has indicated that T. chuii supplementation can improve recovery from exercise-induced muscle damage.
Previous in vitro research with the ingredient in human skeletal muscle myoblasts observed that changes in proteins occurred via the transcriptional responses of genes encoding antioxidant enzymes and the further regulation of polypeptide translation downstream of these events. Specifically, a parallel and positive response in enzyme activities and transcripts for SOD, CAT, and GSH-Px encoding genes in myoblasts was found as a consequence of microalga Tetraselmis chuii treatment. This finding appears to unravel the potential molecular basis of the cytoprotective effect of the ingredient in relation to the primary antioxidant enzymes.
EPA's main function is to produce chemicals called eicosanoids, which help to reduce inflammation and promote joint health. EPA may also help reduce symptoms of depression and improve mental health. In animal models of exercise, phytoplankton supplementation has been associated with reduced levels of proinflammatory cytokines. Marine phytoplankton in exercising rats decreased intramuscular levels and serum concentrations of tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), and intramuscular concentrations of malondialdehyde.
The microalga Phaeodactylum tricornutum is distinguished by its rich nutrient profile, characterized by well-documented neuroprotective activities, including fucoxanthin (FX), a major carotenoid, and polyunsaturated omega-3 fatty acids (n-3 PUFA). In preclinical models, the microalgae extract of Phaeodactylum tricornutum regulates neuroinflammation and oxidative stress following D-galactose induction in mice, exhibiting a dose-response effect.
Microalgae, as a marine-derived natural ingredient, has emerged as a rich source of bioactive compounds with the potential to modulate gut–brain axis activities. Microalgae contain numerous nutrients (e.g., vitamins, minerals, polyunsaturated fatty acids) and phytochemicals with bioactive properties including pigmented compounds (e.g., carotenoids, chlorophyll), polyphenols, and sterols.
The area with the most direct human clinical evidence is exercise recovery, with several randomized controlled trials (RCTs) examining the specific species Tetraselmis chuii.
Study 1 (Sharp et al., 2020, Nutrients): This study investigated the impact of antioxidant supplementation on exercise in a more practical competition environment. Scientists isolated a unique source of marine phytoplankton, microalga Tetraselmis chuii (Oceanix, Lonza Consumer Health). The human arm of this study involved repeated high-intensity exercise bouts; the animal arm examined antioxidant capacity mechanistically. All projects reported in this manuscript were supported by Lonza Consumer Health Inc. — a notable conflict of interest to consider when interpreting results.
Study 2 (Sharp et al., 2021, Physical Activity and Nutrition): This study investigated the effects of marine phytoplankton supplementation (Oceanix®, Tetraselmis chuii) on maximal isometric strength and immune function in healthy humans following a one-week high-intensity resistance-training program, as well as the proinflammatory cytokine response to exercise in a rat model. In the human trial, 22 healthy male and female participants were randomly divided into marine phytoplankton and placebo groups. Following baseline testing, participants underwent a 14-day supplement loading phase before completing five consecutive days of intense resistance training. In the human model, marine phytoplankton prevented significant declines in the isometric peak rate of force development compared to placebo. Additionally, salivary immunoglobulin A (sIgA) concentration was significantly lower following the resistance training protocol in the placebo group but not in the marine phytoplankton group. Supplementation with the microalga Tetraselmis chuii improved short-term recovery, reduced functional muscle damage, and better preserved immune function during the fatiguing period.
Study 3 (Sharp et al., 2021, Physical Activity and Nutrition — long-term overreaching trial): The results indicate that 25 mg of daily marine phytoplankton (Tetraselmis chuii) supplementation improved long-term recovery during a 5-week training program designed to induce non-functional overreaching. Results indicate that marine phytoplankton prompted positive changes in perceived recovery at post-testing, and while both marine phytoplankton and placebo conditions demonstrated decreased peak and mean rate of force development following the overreaching weeks, placebo remained decreased at post-testing while marine phytoplankton returned to baseline levels.
Study 4 (2025, randomized crossover trial, Tetraselmis chuii and NRF2): Human research has indicated that T. chuii supplementation can improve recovery from exercise-induced muscle damage. Superoxide dismutase-rich Tetraselmis chuii has been reported to increase gene expression of NRF2 and related antioxidant enzymes in myoblast tissue culture models. Healthy participants underwent 14 days of supplementation with 25 mg·day⁻¹ T. chuii and placebo in a randomized, double-blind, crossover experimental design.
Evidence assessment: While research on human supplementation is emerging, existing controlled studies indicate promising effects, particularly in healthy adults undergoing resistance training. The evidence quality is considered moderate, with a few randomized controlled trials providing valuable insights, though comprehensive systematic reviews or meta-analyses are still lacking. The predominance of industry-funded trials and small sample sizes are further limitations.
A randomized controlled trial with 22 participants found that marine phytoplankton prevented declines in peak rate of force development and preserved salivary immunoglobulin A after intense training, indicating significant immune support. Additionally, animal models suggest secondary benefits including reduced proinflammatory cytokines (TNF-α, IL-1β) and oxidative stress markers, pointing to anti-inflammatory and antioxidant properties.
Salivary IgA (sIgA) is widely used as a mucosal immunity marker; its preservation in the phytoplankton-treated group, compared to a significant decline in the placebo group, is a clinically relevant finding. However, the small sample size (n=22) and single-study basis necessitate replication before firm conclusions can be drawn.
The evidence base for cognitive benefits comes primarily from studies on the diatom Phaeodactylum tricornutum and its constituent fucoxanthin.
Aging and Memory (Goodbody et al., 2025, Frontiers in Aging): Aging is often associated with cognitive decline and memory impairment, with inflammatory cytokines and oxidative stress markers implicated in this natural process. Microalgae extracts are a natural source of many bioactive compounds that reduce inflammation and oxidative stress, and represent an innovative dietary approach to ameliorate age-related cognitive decline. A proof-of-concept CONSORT-compliant, double-blind, randomized controlled study was conducted to evaluate the effect of daily supplementation of microalgae extract on cognitive function, mood, stress, and inflammation of healthy older adults with mild cognitive impairment over a 24-week period. Sixty-six volunteers with age-associated memory impairment (age 55–75 years) were randomly assigned to ingest a placebo (maltodextrin) or 550 mg of Phaeodactylum tricornutum extract (containing 4.4 mg of fucoxanthin, PUFAs, and saturated fatty acids).
Cognitive function in older adults with perceived decline (Lopresti et al., 2024, Nutrients): Phaeodactylum tricornutum is a microalgae extract containing fucoxanthin and has been shown to enhance cognitive function in younger populations. This study assessed if PT supplementation affects cognition in healthy, young-old, physically active adults with self-perceptions of cognitive and memory decline. Forty-three males and females (64.3 ± 6.0 years) with perceptions of cognitive and memory decline completed the double-blind, randomized, parallel-arm, placebo-controlled intervention clinical trial.
Preclinical cognitive research: Data from animal models are described as promising, advocating for the promotion of the microalgae extract of Phaeodactylum tricornutum (PT) as a natural and viable alternative in the dietary supplement arena for improving cognitive function in humans. Notably, Leonard et al. (2023) demonstrated that both acute and 30-day ingestion of two different doses of the same microalgae extract of PT tested, combined with guarana, improved reaction times, reasoning, learning, executive control, attention shifting, and impulsiveness in e-gamers.
DHA contributes to the maintenance of normal brain function — an EFSA-authorized claim at 250 mg daily intake. Because phytoplankton is EPA-rich rather than DHA-rich, the brain function claim applies more directly to a phytoplankton-plus-DHA-supplement combination than to phytoplankton on its own.
Evidence assessment: Results from the emerging clinical trials are preliminary but encouraging. Most studies are small (n < 70), relatively short-term, and require independent replication. The animal data cannot be directly extrapolated to humans.
Pilot RCT (Tetradesmus obliquus, Nutrients, 2025): A study investigated whether supplementation with a microalgae extract from Tetradesmus obliquus strain Mi175.B1.a influences gut health and reduces stress and anxiety in healthy adults experiencing mild to moderate gastrointestinal distress. Fifty-six healthy adults (age: 31.9 ± 7.7 years) were enrolled in a randomized, double-blind, placebo-controlled, parallel-arm clinical trial. Participants were randomly allocated to receive capsules containing either 250 mg/day of the extract or a placebo for four weeks. Primary outcomes included assessment of GI symptoms using the Gastrointestinal Symptom Rating Scale (GSRS) and Bristol Stool Scale (BSS).
Evidence assessment: This is a pilot trial in a specific microalgae strain and results are preliminary. It is noted primarily for its methodological quality (randomized, double-blind, placebo-controlled) rather than definitive conclusions.
Pilot RCT in elderly individuals (Stiefvatter et al., 2022, Marine Drugs): Because of age-related risks, anti-inflammatory and anti-oxidative agents such as microalgae are potential candidates for intervention. In a randomized controlled trial, researchers tested Phaeodactylum tricornutum (PT), a microalga rich in EPA, carotenoids, vitamins, and β-glucans, cultured in bioreactors. In this pilot trial, 19 healthy elderly received supplements for two weeks based on either the whole PT, the β-1,3-glucan-rich PT supernatant, the combination thereof, or a comparator product.
Evidence assessment: With 19 subjects and a two-week intervention, this trial is very limited in power and duration. It provides proof-of-concept data only.
Fucoxanthin, a carotenoid widely studied in marine microalgae, is at the heart of scientific research because of its promising bioactive properties for human health. Its unique chemical structure and specific biosynthesis have been examined in depth. The antioxidant, anti-inflammatory, and anti-cancer activities of fucoxanthin have been supported by data from in vitro and in vivo experiments and early clinical trials. Despite these potential benefits, challenges persist, such as limited bioavailability and technological obstacles hindering large-scale production.
Evidence assessment: There is no robust scientific basis for viewing phytoplankton as a cure or primary treatment for serious conditions such as cancer, autoimmune disease, or neurological disorders. Anti-cancer research on phytoplankton-derived compounds is at the preclinical stage.
The cardiovascular effects of phytoplankton are largely attributed to its EPA content. Marine phytoplankton supplements benefit heart health primarily through their omega-3 fatty acid content, especially eicosapentaenoic acid (EPA), known to reduce inflammation and protect the heart. The Nannochloropsis family contains some of the highest EPA levels found in nature. An EFSA-authorised claim states that EPA and DHA contribute to normal heart function at 250 mg/day combined.
Evidence assessment: The cardiovascular benefits attributed to phytoplankton are extrapolated from the established EPA evidence base rather than from phytoplankton-specific human cardiovascular endpoint trials. No large RCTs in this area were identified specifically for phytoplankton supplements.
Tetraselmis chuii is an EFSA-approved novel food and dietary supplement with increasing use in nutraceutical production worldwide. It does not produce toxins, is harmless to other marine species, and has been approved as a 'novel food' by the American Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA).
The authorization of dried Tetraselmis chuii microalgae for use in sauces, condiments, and food supplements is set at levels of 250 mg/day; special salts are authorized at levels of 1.0%.
Recently, Tetraselmis chuii has been approved by the European Food Safety Authority as a novel food. The Scientific Committee of the Spanish Agency for Food Safety and Nutrition has declared that there is no indication that consumption of T. chuii poses a safety concern.
The following dosages have been used in the peer-reviewed clinical studies identified:
The minimum effective dose of marine phytoplankton, specifically Tetraselmis chuii, has been identified as 25 mg/day in human trials. This dosage was shown to be effective in improving exercise recovery and preserving muscle function. While 25 mg/day is the optimal dosage used in current randomized controlled trials, higher doses have been tested in animal models (2.55 and 5.1 mg/kg/day) with beneficial outcomes. The maximum safe dose for humans has not yet been established, but no adverse effects have been reported at the studied dosages.
Typical supplement doses for nutritional purposes range from 2–5 grams per day, though it is important to note that these higher doses reflect general nutritional supplementation guidance and are distinct from the specific low-milligram doses used in the Tetraselmis chuii clinical trials targeting antioxidant/athletic outcomes.
For most adults, at standard supplement doses, there are no significant adverse effects. The organism is not new to science, the species used in supplements is well-characterized, and the doses involved are modest.
Data on very long-term use of high doses in diverse human populations are sparse. Current research supports thinking of phytoplankton as a nutrient- and omega-3-rich microalgae ingredient with interesting potential, rather than as a miracle supplement.
Phytoplankton's naturally occurring vitamin K content creates potential interactions with anticoagulant medications. This nutrient plays a crucial role in blood clotting, meaning supplementation could alter anticoagulant drug effects. Additionally, omega-3 fatty acids at high intakes can themselves affect platelet aggregation. You should avoid stacking very high doses of EPA and DHA from multiple sources without professional guidance, especially if you have bleeding risks or take anticoagulants.
The iodine content in Nannochloropsis-based phytoplankton supplements is generally low, but if you are managing a thyroid condition and monitoring iodine intake closely, checking the product's nutritional information panel or asking the manufacturer directly is advisable.
Phytoplankton is not shellfish, but cross-reactivity in marine allergies is not fully predictable. Individuals with known allergies to marine organisms should exercise caution.
Because phytoplankton may concentrate certain minerals and trace elements, avoiding combining very high doses with multiple other algae-based supplements without professional oversight is advisable. The cultivation method has significant implications for contaminant risk. Products cultivated entirely in sealed photobioreactors, using only ultra-purified seawater, CO2, and sunlight, eliminate exposure to heavy metals, microplastics, pathogens, and ocean pollutants. Open-pond or open-ocean grown algae do not carry the same assurance.
Because phytoplankton is often marketed as "detoxifying," it is sometimes layered with herbal detox programs or fasting protocols. This is usually unnecessary and in some cases unwise, especially if you have underlying health conditions. It is safer to integrate phytoplankton into a balanced eating pattern rather than pairing it with extreme diets.
Marine phytoplankton sits at the intersection of genuine nutritional science and supplement marketing that has run well ahead of the data. Claims range from solid (omega-3 content) to speculative (liver detoxification) to outright misleading (cure-all superfood).
When reading about phytoplankton online, claims can range from modest nutritional support to bold promises about detoxification and disease prevention. The actual evidence is more cautious. Most solid data come from broader research on microalgae as food ingredients rather than from branded phytoplankton products tested in large human trials.
There is no robust scientific basis for viewing phytoplankton as a cure or primary treatment for serious conditions such as cancer, autoimmune disease, or neurological disorders. Nutrient-dense microalgae can complement, but not replace, evidence-based medical care.
Health conditions that Phytoplankton may help support.
Body systems that Phytoplankton may help support.
Go back